ADMA Biologics ADMA Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $146.93M-25.7% | $197.67M+800% | -$28.24M+57.1% | -$65.9M+8.0% | ||
| $7.9M+2.6% | $7.7M+1.3% | $7.6M+6.9% | $7.11M+29.4% | ||
| $20.03M+47.1% | $13.62M+120% | $6.19M+18.6% | $5.22M+49.5% | ||
| $50.4M-57.5% | $118.67M+1,249% | $8.8M+115% | -$59.51M+47.0% | ||
| $22.58M+174% | $8.23M+72.4% | $4.77M-65.7% | $13.91M+3.0% | ||
| -$21.89M-155% | -$8.58M-72.2% | -$4.98M+64.2% | -$13.91M-3.0% | ||
| —— | —— | $0— | —— | ||
| -$44.07M+24.4% | -$58.3M-48.6% | -$39.23M— | —— | ||
| —— | $53.33M+196% | -$55.61M— | —— | ||
| $27.82M-74.8% | $110.45M+2,641% | $4.03M+105% | -$73.42M+41.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does ADMA Biologics's cash flow data come from?
- Every line is extracted from ADMA Biologics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.